Statistik Asas
| LEI | 549300VBKG2LTV1TLY22 |
| CIK | 1739614 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Inhibrx Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| November 14, 2024 |
INBX.V / Inhibrx, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d912078dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Inhibrx, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) May 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39452 Inhibrx, Inc. (Exact name of registrant as specified in its charter |
|
| June 3, 2024 |
INBX / Inhibrx Biosciences, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2406030113ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 5) Inhibrx, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Se |
|
| May 30, 2024 |
As filed with the Securities and Exchange Commission on May 30, 2024 As filed with the Securities and Exchange Commission on May 30, 2024 Registration No. |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2024 Inhibrx, Inc. |
|
| May 30, 2024 |
SECOND AMENDED AND RESTATED BYLAWS OF INHIBRX, INC. (a Delaware corporation) Article I Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF INHIBRX, INC. (a Delaware corporation) Article I Stockholders Section 1. Annual Meetings. The annual meeting of the stockholders of Inhibrx, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time, within or wi |
|
| May 30, 2024 |
SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBRX, INC. Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBRX, INC. FIRST: The name of the corporation is: Inhibrx, Inc. SECOND: The address of the registered office of the Corporation in the State of Delaware is: 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808. The name of its registered agent for service of process in the State of Delaware at such |
|
| May 30, 2024 |
As filed with the Securities and Exchange Commission on May 30, 2024 As filed with the Securities and Exchange Commission on May 30, 2024 Registration No. |
|
| May 30, 2024 |
As filed with the Securities and Exchange Commission on May 30, 2024 As filed with the Securities and Exchange Commission on May 30, 2024 Registration No. |
|
| May 30, 2024 |
As filed with the Securities and Exchange Commission on May 30, 2024 As filed with the Securities and Exchange Commission on May 30, 2024 Registration No. |
|
| May 30, 2024 |
As filed with the Securities and Exchange Commission on May 30, 2024 As filed with the Securities and Exchange Commission on May 30, 2024 Registration No. |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 24, 2024 |
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi Exhibit 99.1 Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi SAN DIEGO – May 24, 2024 – Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx,” or the “Company”) announced that, at a special meeting (the “Special Meeting”), the Company’s stockholders approved the sale to Sanofi of all the assets and liabilities primarily related to INBRX-101, an optimized, recombinant alpha-1 antitrypsin (“AAT”) au |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 Inhibrx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2024 |
Inhibrx Reports First Quarter 2024 Financial Results and Recent Corporate Highlights Exhibit 99.1 Inhibrx Reports First Quarter 2024 Financial Results and Recent Corporate Highlights San Diego, CA, May 9, 2024 – Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a biopharmaceutical company with three programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the first quarter of 2024 and provided an update on recent corporate h |
|
| May 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Inhibrx, Inc. |
|
| May 8, 2024 |
EXHIBIT 99.1 Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger SAN DIEGO, May 8, 2024 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx,” or the “Company”) today announced that it has set a record date of May 17, 2024 (the “Record Date”) for the previously announced distribution by the Compa |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Inhibrx, Inc. |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 Inhibrx, Inc. |
|
| February 29, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Inhibrx, Inc. |
|
| February 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Rule 14a-101) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a- |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 28, 2024 |
26, 2024, by and between the Registrant and Elpiscience Biopharmaceuticals, Inc. Exhibit 10.15 TERMINATION AGREEMENT This Termination Agreement (this “Termination Agreement”), effective as of February 26, 2024 (the “Effective Date”), is made by and between Inhibrx, Inc. (formerly known as Inbrx105 LP), a Delaware corporation located at 11025 N. Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“Inhibrx”), and Elpiscience Biopharmaceuticals, Inc., a Cayman Islands company havin |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. |
|
| February 28, 2024 |
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results Exhibit 99.1 Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results San Diego, CA, February 28, 2024 – Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a biopharmaceutical company with three clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2023. Key Highlights •Sale of INBRX-101 to Sano |
|
| February 14, 2024 |
INBX / Inhibrx, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm246065d14sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* INHIBRX, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2024 |
EX-99.1 2 d771606dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2024 |
INBX / Inhibrx, Inc. / Eckelman Brendan P. - SC 13G/A Passive Investment SC 13G/A 1 sc13gbe-fy2023.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2024 |
INBX / Inhibrx, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Inhibrx, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2024 |
Exhibit 1: Joint filing agreement EX-99.1 2 tm246065d14ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio |
|
| February 14, 2024 |
INBX / Inhibrx, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 ef20021473sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 4) Inhibrx, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Cl |
|
| February 14, 2024 |
INBX / Inhibrx, Inc. / Lappe Mark - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2024 |
INBX / Inhibrx, Inc. / Kayyem Jon Faiz - SC 13G/A Passive Investment SC 13G/A 1 sc13gfk-fy2023.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (a |
|
| January 23, 2024 |
Exhibit 4.1 AGREEMENT RELATING TO THE PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK AND SECURITIES PURCHASE AGREEMENT THIS AGREEMENT (the “Agreement”), dated as of January 22, 2024, amends the Pre-Funded Warrant to Purchase Common Stock, dated August 31, 2023, issued by Inhibrx, Inc., a Delaware corporation (the “Company”), to [●] (the “Holder”) and specifies certain registration and other rights of |
|
| January 23, 2024 |
Exhibit 4.2 AMENDMENT TO WARRANTS TO PURCHASE STOCK THIS AMENDMENT (the “Amendment”), dated as of January 22, 2024, amends each of the 2020 Warrants (as defined below) and the 2022 Warrants (as defined below) that have been issued by Inhibrx, Inc., a Delaware corporation (the “Company”) to Oxford Finance LLC (the “Holder”). WHEREAS, on July 15, 2020, the Company originally issued warrants to purch |
|
| January 23, 2024 |
Exhibit 99.1 Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B Inhibrx, Inc. shareholders will receive per share consideration of $30 per share in cash, a CVR equal to $5, plus 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx, Inc. Sanofi to pay off Inhibrx’s outstanding debt balance and capitalize New Inhibrx wi |
|
| January 23, 2024 |
Exhibit 2.2 EXECUTION VERSION SEPARATION AND DISTRIBUTION AGREEMENT BY AND AMONG INHIBRX, INC., IBEX SPINCO, INC., AND, SOLELY WITH RESPECT TO SECTION 2.7(b), SECTION 2.10, SECTION 3.3, SECTION 4.2, SECTION 4.3, SECTION 4.7, SECTION 5.1, SECTION 6.6(i), SECTION 8.3, SECTION 8.6, SECTION 8.7, AND SECTION 8.8, AVENTIS INC. Dated as of January 22, 2024 NO AGREEMENT, ORAL OR WRITTEN, REGARDING OR RELA |
|
| January 23, 2024 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among AVENTIS INC. ART ACQUISITION SUB, Inc. and INHIBRX, INC. Dated as of January 22, 2024 Table of Contents Page Article I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Effective Time 2 Section 1.3 The Closing 2 Section 1.4 Organizational Documents of the Surviving Corporation 2 Section 1.5 Director |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Inhibrx, Inc. |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Inhibrx, Inc. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 9, 2023 |
Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Exhibit 99.1 Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights San Diego, CA, November 9, 2023 – Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the third quarter of 2023 and provided an update on recent corporat |
|
| November 9, 2023 |
INHIBRX, INC. CLAWBACK POLICY I.Introduction The Compensation Committee of the Board of Directors (the “Committee”) of Inhibrx, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Committee ha |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHI |
|
| November 2, 2023 |
Exhibit 99.1 Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma SAN DIEGO, November 2, 2023 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 |
|
| November 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 19, 2023 |
Exhibit 99.1 Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada SAN DIEGO, /September 19, 2023 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmac |
|
| September 19, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 29, 2023 |
Inhibrx Announces $200 Million Private Placement Financing EX 99.1 Inhibrx Announces $200 Million Private Placement Financing SAN DIEGO, August 29, 2023 / PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has entered into a securities purchase agreement for a private placement financing (the |
|
| August 29, 2023 |
Form of Pre-Funded Warrant to Purchase Common Stock. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICA |
|
| August 29, 2023 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of August 28, 2023, is made by and among Inhibrx, Inc., a Delaware corporation (the “Company”), and the Purchasers listed on Schedule 1 hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS: A. The Company and the Purchasers are e |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 7, 2023 |
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights Exhibit 99.1 Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights San Diego, CA, August 7, 2023 – Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2023 and provided an update on recent corporat |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, |
|
| August 7, 2023 |
inhibrxpresentationaugus INBX Investor Presentation Outcomes Focused August 2023 Innovation Driven 2 Presentation disclaimer This presentation contains forward-looking statements. |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 30, 2023 |
Exhibit 99.1 Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency SAN DIEGO, May 30, 2023 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designati |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, |
|
| May 8, 2023 |
Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Exhibit 99.1 Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights San Diego, CA, May 8, 2023 – Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2023 and provided an update on recent corporate highli |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 26, 2023 |
Exhibit 99.1 Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials SAN DIEGO, April 26, 2023/PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has initiated a registration |
|
| April 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Schedule 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Schedule 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 9, 2023 |
INBX / Inhibrx Inc / Inhibrx, Inc. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| March 9, 2023 |
INBX / Inhibrx Inc / Inhibrx, Inc. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| March 9, 2023 |
INBX / Inhibrx Inc / Inhibrx, Inc. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. |
|
| March 6, 2023 |
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results Exhibit 99.1 Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results San Diego, CA, March 6, 2023 – Inhibrx, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2022. Key Highlights •INBRX-101: Timing for the pote |
|
| March 6, 2023 |
inhibrxpresentationmarch Outcomes Focused Innovation Driven March 2023 2 Presentation disclaimer This presentation contains forward-looking statements. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 6, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inhibrx, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 — Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, $0 |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 REGISTRATION NO. |
|
| February 14, 2023 |
INBX / Inhibrx Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 brhc10047904sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) Inhibrx, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of |
|
| February 14, 2023 |
INBX / Inhibrx Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2023 |
INBX / Inhibrx Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d371754dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Inhibrx, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2023 |
EX-99.1 2 d371754dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| November 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 16, 2022 |
Exhibit 99.2 Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma SAN DIEGO, November 16, 2022 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated efficacy and safety d |
|
| November 16, 2022 |
Outcomes Focused Innovation Driven November 2022 2 This presentation contains forward-looking statements. |
|
| November 7, 2022 |
Exhibit 10.2 THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Third Amended and Restated Executive Employment Agreement (this ?Agreement?) is effective as of January 1, 2023 (the ?Effective Date?) by and between Inhibrx, Inc., a Delaware corporation (the ?Company?), and Mark Lappe (?Executive?). WHEREAS, Executive is currently employed by the Company, pursuant to the terms of that ce |
|
| November 7, 2022 |
Exhibit 10.3 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Second Amended and Restated Executive Employment Agreement (this ?Agreement?) is effective as of January 1, 2023 (the ?Effective Date?) by and between Inhibrx, Inc., a Delaware corporation (the ?Company?), and Kelly Deck (?Executive?). WHEREAS, Executive is currently employed by the Company, pursuant to the terms of that |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHI |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 7, 2022 |
Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights San Diego, CA, November 7, 2022 ? Inhibrx, Inc. (Nasdaq: INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the third quarter of 2022 and provided an update on recent corporate highlights. Recent Corporate |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 17, 2022 |
INBX / Inhibrx Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INHIBRX, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45720L 107 (CUSIP Number) October 7, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| October 4, 2022 |
Exhibit 10.1 SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SIXTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of October 3, 2022 (the ?Sixth Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such ca |
|
| October 4, 2022 |
Outcomes Focused Innovation Driven October 2022 2 This presentation contains forward-looking statements. |
|
| October 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 4, 2022 |
Exhibit 99.2 Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study SAN DIEGO, October 4, 2022 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare disea |
|
| September 23, 2022 |
Inhibrx, Inc. 11025 N. Torrey Pines Rd., Suite 200 La Jolla, CA 92037 September 23, 2022 Inhibrx, Inc. 11025 N. Torrey Pines Rd., Suite 200 La Jolla, CA 92037 September 23, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Sasha Parikh and Tracie Mariner Re: Inhibrx, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed February 28, 2022 Form 10-Q for the Fiscal Quarter Ended June 30, 2022 Fi |
|
| August 15, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 15, 2022 |
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma SAN DIEGO, August 15, 2022 /PRNewswire/ - Inhibrx, Inc. |
|
| August 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 10, 2022 |
Outcomes Focused Innovation Driven August 2022 2 This presentation contains forward-looking statements. |
|
| August 8, 2022 |
Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights San Diego, CA, August 8, 2022 ? Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the second quarter of 2022 and provided an update on recent corporate highlights. Recent Corporate High |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 19, 2022 |
INBX / Inhibrx Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Inhibrx, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) July 5, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| July 19, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| June 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 30, 2022 |
Exhibit 99.2 Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance San Diego, CA, June 30, 2022 ? Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a robust preclinical pipeline, today announced the completion of Phase 1 dose escala |
|
| June 30, 2022 |
Outcomes Focused Innovation Driven July 2022 2 This presentation contains forward-looking statements. |
|
| June 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 16, 2022 |
Exhibit 10.1 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIFTH AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of June 15, 2022 (the ?Fifth Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capa |
|
| May 25, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 16, 2022 |
Outcomes Focused Innovation Driven May 2022 2 This presentation contains forward-looking statements. |
|
| May 16, 2022 |
Exhibit 99.2 INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing ?Topline results from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events. ?Topline data from the multiple ascending dose co |
|
| May 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, |
|
| May 9, 2022 |
Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights Exhibit 99.1 Inhibrx Reports First Quarter 2022 Financial Results and Recent Corporate Highlights San Diego, CA, May 9, 2022 ? Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the first quarter of 2022 and provided an update on recent corporate highlights. Recent Corporate Highlight |
|
| April 25, 2022 |
Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 Exhibit 99.1 Inhibrx Announces Formation of Scientific Advisory Board for INBRX-101 SAN DIEGO, April 25, 2022 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced the formation of a Scientific Advisory Board (?SAB?) for its INBRX-101 program for the treatment of alpha-1 antitrypsin deficiency |
|
| April 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 13, 2022 |
DEFA14A 1 inbx2022additionalproxymat.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Schedule 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Schedule 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| April 5, 2022 |
Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting EX-99.1 2 ex991inbxtopresentatats.htm EX-99.1 Exhibit 99.1 Inhibrx to Present INBRX-101 Data at ATS 2022 Annual Meeting SAN DIEGO, April 5, 2022 – Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that late-breaking data from INBRX-101 will be presented at the American Thoracic Society (“ATS”) 202 |
|
| April 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 4, 2022 |
Outcomes Focused Innovation Driven April 2022 2 This presentation contains forward-looking statements. |
|
| April 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 3, 2022 |
Exhibit 99.1 Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency ?Interim results reported in October 2021 from the Phase 1 study showed a favorable safety and tolerability profile with no drug-related severe or serious adverse events at doses up to and including 120 mg/kg single dose and 80 mg/kg multi-dose administered intravenously, or |
|
| March 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Inhibrx, Inc. (Exact name of Registrant as Specified in its Charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, $0 |
|
| March 2, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 REGISTRATION NO. |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. |
|
| February 28, 2022 |
11025 N. Torrey Pines Rd Suite 200 La Jolla, CA 92037 February 1, 2022 Via Hand Delivery Klaus Wagner Re: Final Day of Employment with Inhibrx Dear Klaus: In light of your resignation, this letter serves as confirmation that your employment with Inhibrx (the ?Company?) is voluntarily terminated as of February 1, 2022 (the ?Separation Date?). You have received or will receive payment on the Separat |
|
| February 28, 2022 |
EX-99.1 2 exhibit99112312021.htm EX-99.1 Exhibit 99.1 Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights San Diego, CA, February 28, 2022 – Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the fourth quarter and fiscal year 2021 and |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 22, 2022 |
EX-10.1 2 exhibit101fourthamendmentt.htm EX-10.1 Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of February 18, 2022 (the “Fourth Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virg |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 22, 2022 |
Inhibrx Announces Amended Loan Agreement with Oxford Exhibit 99.1 Inhibrx Announces Amended Loan Agreement with Oxford San Diego, CA, February 22, 2022 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that it has amended its loan and security agreement with Oxford Finance LLC (?Oxford?). ?This amendment further strengthens our balance sheet |
|
| February 14, 2022 |
INBX / Inhibrx Inc / Inhibrx, Inc. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2022 |
INBX / Inhibrx Inc / Inhibrx, Inc. - SC 13G/A Passive Investment SC 13G/A 1 sc13gfkfebruary2022.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 14, 2022 |
INBX / Inhibrx Inc / Inhibrx, Inc. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2022 |
INBX / Inhibrx Inc / Inhibrx, Inc. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2022 |
INBX / Inhibrx Inc / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Inhibrix, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45720L107 (CUSIP Numb |
|
| February 9, 2022 |
INBX / Inhibrx Inc / LAV Summit Ltd - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.1)* Inhibrx, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45720L107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| January 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 4, 2022 |
EX-99.2 3 inhibrxpresentationjanua.htm EX-99.2 Outcomes Focused Innovation Driven January 2022 2 This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology i |
|
| January 4, 2022 |
Exhibit 99.1 Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda? (Pembrolizumab) Along with Updated Single Agent Data ?Two durable partial responses in checkpoint inhibitor-naive nasopharyngeal carcinoma and uveal melanoma patients in dose escalation of INBRX-106 in combination with Keytruda? ?Durable single agent- |
|
| December 1, 2021 |
Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma EX-99.1 2 exhibit991pressrelease1220.htm EX-99.1 Exhibit 99.1 Inhibrx Receives FDA Orphan-Drug Designation for INBRX-109 in Chondrosarcoma –Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma –Preliminary median progression-free survival (PFS) of 7.4 months and disease control rate of 89% observed in conventional chondrosarcoma patients in ong |
|
| December 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 9, 2021 |
EX-10.5 5 exhibit105deckemploymentag.htm EX-10.5 Exhibit 10.5 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”) is effective as of January 1, 2022 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Kelly Deck (“Executive”). WHEREAS, Executive is currently employed by the Comp |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHI |
|
| November 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 9, 2021 |
Exhibit 10.2 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Second Amended and Restated Executive Employment Agreement (this “Agreement”) is effective as of January 1, 2022 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Mark Lappe (“Executive”). WHEREAS, Executive is currently employed by the Company, pursuant to the terms of that |
|
| November 9, 2021 |
Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Exhibit 99.1 Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights San Diego, CA, November 9, 2021 ? Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the third quarter of 2021 and provided an update on recent corporate highlights. Recent Corporate High |
|
| November 9, 2021 |
Exhibit 10.3 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Second Amended and Restated Executive Employment Agreement (this ?Agreement?) is effective as of January 1, 2022 (the ?Effective Date?) by and between Inhibrx, Inc., a Delaware corporation (the ?Company?), and Klaus Wagner (?Executive?). WHEREAS, Executive is currently employed by the Company, pursuant to the terms of tha |
|
| November 9, 2021 |
Exhibit 10.4 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Second Amended and Restated Executive Employment Agreement (this “Agreement”) is effective as of January 1, 2022 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Brendan Eckelman (“Executive”). WHEREAS, Executive is currently employed by the Company, pursuant to the terms of |
|
| October 28, 2021 |
Exhibit 99.1 Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors SAN DIEGO, October 28, 2021 /PRNewswire/ - Inhibrx, Inc. (Nasdaq: INBX), announced the appointment of three key executives: David Matly, M.B.A., as Chief Commercial Officer; David Kao, PharmD, M.B.A., RPh, as Vice President of Regulator |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 12, 2021 |
EX-99.1 2 exhibit991pressreleaseocto.htm EX-99.1 Exhibit 99.1 INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels with Monthly Dosing –Interim results from the Phase 1 study show a favorable safety and tolerability profile with no drug-related severe or serious adverse events at doses u |
|
| October 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 12, 2021 |
Outcomes Focused Innovation Driven October 2021 2 This presentation contains forward-looking statements. |
|
| September 3, 2021 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM September 3, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Inhibrx, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares of the Company?s common stock, p |
|
| September 3, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 3, 2021 |
As filed with the Securities and Exchange Commission on September 3, 2021. Table of Contents As filed with the Securities and Exchange Commission on September 3, 2021. |
|
| September 3, 2021 |
Form of Subordinated Indenture Exhibit 4.8 INHIBRX, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04( |
|
| September 3, 2021 |
Exhibit 4.7 INHIBRX, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) 5.04 |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, |
|
| August 9, 2021 |
Inhibrx Reports Second Quarter 2021 Financial Results EX-99.1 2 exhibit99106302021.htm EX-99.1 Exhibit 99.1 Inhibrx Reports Second Quarter 2021 Financial Results San Diego, CA, August 9, 2021 – Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the second quarter of 2021. Financial Results •Cash and Cash Equivalents. As of June 30, 2021, Inhibrx had cash and cash equi |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 21, 2021 |
Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Loan and Security Agreement (this ?Amendment?) is entered into as of June 18, 2021 (the ?Third Amendment Date?), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (?Oxford?), as collateral agent (in such capa |
|
| June 21, 2021 |
Outcomes Focused Innovation Driven June 2021 2 This presentation contains forward-looking statements. |
|
| June 21, 2021 |
EX-99.1 3 june2021chondropr.htm EX-99.1 EXHIBIT 99.1 Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patients, Updates Data for Ongoing Phase 1 Study and Announces Amended Loan Agreement with Oxford –Median progression-free survival (PFS) of 7.6 months and disease control rate of 87.5% observed in conventional chondrosarcoma patients in |
|
| June 9, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L107 (CUSIP Number) May 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| May 13, 2021 |
Inhibrx Reports First Quarter 2021 Financial Results Exhibit 99.1 Inhibrx Reports First Quarter 2021 Financial Results San Diego, CA, May 13, 2021 ? Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter of 2021. ?This past quarter, we continued to make significant progress advancing our clinical programs and are on track to deliver data from all four p |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark one) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Schedule 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (a |
|
| April 28, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Schedule 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the |
|
| March 12, 2021 |
Outcomes Focused Innovation Driven March 2021 2 This presentation contains forward-looking statements. |
|
| March 12, 2021 |
Description of the Registrant’s Securities. Exhibit 4.4 DESCRIPTION OF INHIBRX, INC.?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 We have one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act: common stock, $0.0001 par value per share. Unless the context otherwise requires, all references to ?we?, ?us?, the ?Company?, or ?Inhibrx? |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. |
|
| March 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 12, 2021 |
Exhibit 99.1 Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist San Diego, CA, March 12, 2021 ? Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Inhibrix, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45720L107 (CUSIP Nu |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2020 (Date o |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2020 (Date o |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2020 (Date o |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. )* INHIBRX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45720L 107 (CUSIP Number) December 31, 2020 (Date o |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Inhibrx, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45720L107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| January 19, 2021 |
As filed with the Securities and Exchange Commission on January 19, 2021 REGISTRATION NO. |
|
| January 13, 2021 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 13, 2021 |
EX-99.1 2 exhibit991pressreleasefpr1.htm EX-99.1 Exhibit 99.1 Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year San Diego, CA, January 13, 2021 – Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with |
|
| January 5, 2021 |
Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist EX-99.1 2 exhibit991pressrelease1520.htm EX-99.1 Exhibit 99.1 Inhibrx Announces Phase 1 Dose Escalation Results of INBRX-106, a Novel Hexavalent OX40 Agonist San Diego, CA January 5, 2021 – Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today results from Part 1 of the Phase 1 dose escalation trial of INBRX-106, a |
|
| January 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2021 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 5, 2021 |
Outcomes Focused Innovation Driven January 2021 2 This presentation contains forward-looking statements. |
|
| November 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2020 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark one) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39452 INHIBRX, INC. |
|
| November 13, 2020 |
Exhibit 99.1 Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford •Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th •Additional $20 million in cash with an additional future option of $20 million through Oxford loan amendment •First registration |
|
| November 13, 2020 |
Exhibit 10.11 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of November 12, 2020 (the “First Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity |
|
| November 12, 2020 |
Innovation Driven Outcomes Focused November 2020 Presentation disclaimer The Company may not actually achieve the plans, intentions or expectations disclosed in its This presentation contains forward-looking statements. |
|
| November 12, 2020 |
Exhibit 99.1 Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients ?Disease control observed in 92% of patients ?Conference call to be held today at 2:30pm PT San Diego, CA, November 11, 2020 ? Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 c |
|
| November 12, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 11, 2020 |
EX-99.1 2 inhibrxpresentationsepte.htm EX-99.1 Innovation Driven Outcomes Focused September 2020 Presentation disclaimer The Company may not actually achieve the plans, intentions or expectations disclosed in its This presentation contains forward-looking statements. In some cases, you can forward-looking statements, and you should not place undue reliance on the Company’s identify forward-looking |
|
| September 11, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2020 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 31, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Inhibrx, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 45720L107 (CUSIP Number) August 21, 2020 |
|
| August 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2020 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 001-39452 82-4257312 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 21, 2020 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBRX, INC. (originally incorporated on November 17, 2017 under the name Tenium Therapeutics, Inc.) FIRST: The name of the Corporation is Inhibrx, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, New Castle County, Delaware 19808. The name |
|
| August 21, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INHIBRX, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 1 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 1.10 Nomination of Directors 2 1.11 Notice of Business at Annual Meetings 4 1.12 Conduct of Meetings 6 |
|
| August 19, 2020 |
Filed pursuant to Rule 424(b)(4) Registration Nos. 333-240135 and 333-248115 PROSPECTUS 7,000,000 Shares Common Stock We are offering 7,000,000 shares of our common stock. This is our initial public offering, and no public market currently exists for our common stock. The initial public offering price is $17.00 per share. Our common stock has been approved for listing on the Nasdaq Global Market u |
|
| August 19, 2020 |
As filed with the Securities and Exchange Commission on August 19, 2019 REGISTRATION NO. |
|
| August 18, 2020 |
As filed with the Securities and Exchange Commission on August 18, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 2836 82-4257312 (State or other jurisdiction of incorporation or organization) (Primary St |
|
| August 14, 2020 |
INHIBRX, INC. 11025 N. TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037 August 14, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Mary Beth Breslin Ms. Laura Crotty Ms. Jeanne Bennett Ms. Kate Tillan RE: Inhibrx, Inc. Registration Statement on Form S-1 File No. 333-240135 Acceleration Request Requested Date: |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Inhibrx, Inc. (Exact name of registrant as specified in its charter) Delaware (State of incorporation or organization) 82-4257312 (I.R.S. Employer Identification No.) 11025 N. Torrey Pines Road, |
|
| August 14, 2020 |
August 14, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 12, 2020 |
Exhibit 10.5 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”) is effective as of August 7, 2020 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Klaus Wagner (“Executive”). WHEREAS, Executive is currently employed by the Company, pursuant to the terms of that certain Execu |
|
| August 12, 2020 |
Power of Attorney (included on signature page to the Prior Registration Statement). As filed with the Securities and Exchange Commission on August 12, 2020 . Registration No. 333-240135 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 2836 82-4257312 (State or other jurisdiction of incorporation or |
|
| August 12, 2020 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBRX, INC. (originally incorporated on November 17, 2017 under the name Tenium Therapeutics, Inc.) FIRST: The name of the Corporation is Inhibrx, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, New Castle County, Delaware 19808. The name |
|
| August 12, 2020 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.3 CERTIFICATE OF AMENDMENT TO FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBRX, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Inhibrx, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1.The name of the Corporation is |
|
| August 12, 2020 |
Exhibit 10.3 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”) is effective as of August 7, 2020 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Mark Lappe (“Executive”). WHEREAS, Executive is currently employed by the Company, pursuant to the terms of that certain Executi |
|
| August 12, 2020 |
Exhibit 10.8 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is effective as of August 7, 2020 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Kelly Deck (“Executive”). 1.Roles and Duties. Subject to the terms and conditions of this Agreement, the Company shall employ Executive as its Chief Financial Officer rep |
|
| August 12, 2020 |
Form of Underwriting Agreement. Exhibit 1.1 [●] SHARES INHIBRX, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT [●], 2020 Jefferies LLC Evercore Group L.L.C. Credit Suisse Securities (USA) LLC c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 1001 |
|
| August 12, 2020 |
Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan. Exhibit 10.13 INHIBRX, INC. AMENDED AND RESTATED 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Inhibrx, Inc. Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors |
|
| August 12, 2020 |
Exhibit 10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”) is effective as of August 7, 2020 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Brendan Eckelman (“Executive”). WHEREAS, Executive is currently employed by the Company, pursuant to the terms of that certain E |
|
| August 5, 2020 |
3580 Carmel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com August 5, 2020 VIA EDGAR & OVERNIGHT MAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Office of Healthcare & Insurance Re: Inhibrx, Inc. Registration Statement on Form S-1 Filed July 28, 2020 File No. 333-240135 Ladies and Gentlemen: We are subm |
|
| August 3, 2020 |
Jeremy D. Glaser 858 314 1515 [email protected] 3580 Carmel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR THE OMITTED PORTIONS, WHICH HAVE BEEN REPLACED WITH THE PLACEHOLDER “[***].” August 3, 2020 VIA EDGAR AND COURIER S |
|
| July 28, 2020 |
Exhibit 10.24 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THEY MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. ANY PROPOSED TR |
|
| July 28, 2020 |
Exhibit 10.27 [Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.] Option and License Agreement This Option and License Agreement (this “Agreement”), effective as of J |
|
| July 28, 2020 |
Exhibit 4.2 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 5 2.3 Underwriting Requirements 5 2.4 Obligations of the Company 6 2.5 Furnish Information 7 2.6 Expenses of Registration 7 2.7 Delay of Registration 7 2.8 Indemnification 7 2.9 Reports Under Exchange Act 9 2.10 Limi |
|
| July 28, 2020 |
Exhibit 10.28 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of July 15, 2020 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent ( |
|
| July 28, 2020 |
Exhibit 10.23 INHIBRX, INC. AMENDMENT TO CONVERTIBLE PROMISSORY NOTE This AMENDMENT (the “Amendment”) to that certain Convertible Promissory Note listed on Schedule A hereto (the “Note”) issued pursuant to the terms of that certain Note Purchase Agreement by and among the Inhibrx, Inc., a Delaware corporation (the “Company”) and DRAGSA 50 LLC (the “Investor”), dated as of May 20, 2019 (the “Purcha |
|
| July 28, 2020 |
Fourth Amended and Restated Certificate of Incorporation of the Registrant (currently in effect). Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBRX, INC. Inhibrx, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. The name of the corporation is Inhibrx, Inc. The corporation was originally incorporated under the name of Teni |
|
| July 28, 2020 |
Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF INHIBRX, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 1 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 1.10 Nomination of Directors 2 1.11 Notice of Business at Annual Meetings 4 1.12 Conduct of Meetings 6 |
|
| July 28, 2020 |
Non-Employee Director Compensation Policy Exhibit 10.31 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY INHIBRX, INC. The Board of Directors of Inhibrx, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”), which establishes compensation to be paid to non-employee directors of the Company, effective upon the completion of the Company’s initial public offering (“Effective Time”), to provide an |
|
| July 28, 2020 |
As filed with the Securities and Exchange Commission on July 27, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INHIBRX, INC. (Exact name of registrant as specified in its charter) Delaware 2836 82-4257312 (State or other jurisdiction of incorporation or organization) (Primary Stan |
|
| July 28, 2020 |
Exhibit 10.9 INHIBRX, INC. AMENDED AND RESTATED 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Inhibrx, Inc. Amended and Restated 2017 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, |
|
| July 28, 2020 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INHIBRX, INC. (originally incorporated on November 17, 2017 under the name Tenium Therapeutics, Inc.) FIRST: The name of the Corporation is Inhibrx, Inc. SECOND: The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, New Castle County, Delaware 19808. The name |
|
| July 28, 2020 |
Form of Indemnification Agreement. Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (“Agreement”) is made as of [l], by and between INHIBRX, INC., a Delaware corporation (the “Company”), and [l] (the “Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, highly competent persons hav |
|
| July 28, 2020 |
Form of Warrant to Purchase Stock by and between the Registrant and Oxford Finance LLC. Exhibit 4.6 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| July 28, 2020 |
Exhibit 4.5 SECOND AMENDMENT TO RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT THIS SECOND AMENDMENT TO RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Amendment”), is made and effective as of April 6, 2020 (the “Effective Date”), to amend that certain Right of First Refusal and Co-Sale Agreement, dated as of April 30, 2018, as amended by that First Amendment to Right of First Refusal and Co-Sal |
|
| July 28, 2020 |
Exhibit 10.30 [Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.] Amendment No. 1 to Amended and Restated Master Services Agreement This Amendment No. 1 (this “Amendm |
|
| July 27, 2020 |
3580 Carmel Mountain Road Suite 300 San Diego, CA 92130 858 314 1500 mintz.com July 27, 2020 VIA EDGAR & OVERNIGHT MAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Office of Healthcare & Insurance Re: Inhibrx, Inc. Draft Registration Statement on Form S-1 Submitted June 26, 2020 CIK No. 0001739614 (the “Draft Registration |
|
| June 26, 2020 |
EX-3.5 3 filename3.htm Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF INHIBRX, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 1 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 2 1.10 Nomination of Directors 2 1.11 Notice of Business at Annual Meetings 4 1.12 |
